This is one of the newsletters I got (at 3:15 PM CST) in my inbox:
PSP Free Members,
As you know, Pharmaceutical stocks have been on fire lately!
So, I went searching, and discovered a new Pharma pick that I believe could be on the verge of having a breakout year in 2013!
This is a relatively little known company called ScripsAmerica Inc., (SCRC).
SCRC is a leading supplier of prescription, OTC and nutraceutical drugs, and while the company is not quite in the black yet; SCRCis already rolling out $1-Million dollar quarterly revenues, which is rather impressive for a company that received their first purchase order in 2010.
SCRC Issues Late-Breaking News:
SCRC issued exceptional news late on Friday regarding their current acquisition target Marlex Pharmaceuticals; announcing that the company hassignificantly increased production on their $25-Million dollar DOD contract.
In September, SCRC signed an LOI to acquire Marlex Pharmaceuticals, and the company expects to finalize this acquisition in the first quarter of 2013.
But what really has me excited about SCRC's potential, is a Sept. 12th press release in which the CEO of ScripsAmerica stated, "the acquisition of Marlex Pharmaceuticals will position ScripsAmerica to increase its annual revenues by up to $6-Million."
According to the CEO, when the acquisition of Marlex Pharmaceuticals is finalized, it is expected to not only increase company revenues by up to $6-Million, but immediately increase operating income by up to 10 - 15%!
As you can see, SCRC is not your typical penny stock. This is a real company, with real revenues, and absolutely huge potential!
Make sure you take a serious look at SCRC as soon as possible. Trading at only $0.31 per share, SCRC looks like it could be a major winner for us as we head into the first quarter of 2013!
Do your research right away, and lets be ready for Monday's session!
-James
NEW PICK
ScripsAmerica Inc. SCRC
Currently Trading: $0.31
PSP Free Members,
Our new pick is SCRC!
SCRC is currently trading at only $0.31 per share, but I don't expect that price to last for much longer due to recent developments.
As you probably already know, pharmaceutical stocks have been surging in the first few weeks of 2013, and I believe that trend will likely continue in the first quarter of this year.
SCRC is in the process of completing a major acquisition that is expected to immediatly increase revenue once it is complete. As I mentioned above this is a company already producing strong revenues, and I believe it has major potential heading into 2013!
About ScripsAmerica, Inc.: Founded in 2008 and based in New Castle, Delaware, ScripsAmerica, Inc. distributes prescription and over the counter (OTC) pharmaceuticals in the United States. It provides pharmaceutical supply chain management services, from strategic sourcing to delivering niche generic pharmaceuticals to market. The company delivers pharmaceutical products to a range of customers across the health care industry, including physician's offices, retail pharmacies, long-term care sites, hospitals, and government and home care agencies.
ScripsAmerica's CEO Issues Positive Outlook for 2013 With Significant Developments Expected During the First Quarter:
ScripsAmerica, Inc. announced that its CEO, Bob Schneiderman, issued a very positive outlook for 2013, citing how the Company expects to finalize the pending acquisition of Marlex Pharmaceuticals and launch its RapiMed children's pain reliever during the first quarter.
Mr. Schneiderman discussed the Company's future during an interview with "The News Journal," also known as , for an article that was featured in the publication's November 25th edition. Titled "," the feature also highlights the fact that ScripsAmerica could potentially double its revenue during 2013 as a result of these significant developments and that management's goal is to implement a regional launch of the RapiMed product line shortly after the beginning of the year.
SCRC Target Acquisition Marlex Pharmaceuticals Renews Supply Contract With National Nursing Home Chain:
ScripsAmerica, Inc. announced that Marlex Pharmaceuticals, which the Company has signed a Letter of Intent to acquire, has renewed its pharmaceutical supply contract with national nursing home chain, GeriMed.
The new agreement extends through September 2014 and can potentially generate $2 million in revenue for Marlex Pharmaceuticals, which ScripsAmerica plans to operate as a wholly owned subsidiary upon its acquisition being finalized. Prior to this renewal, GeriMed and Marlex were engaged in a two year pharmaceutical packaging and distribution agreement.
ScripsAmerica's Acquisition Target, Marlex Pharmaceuticals, Significantly Increases Production on its $25 Million DOD Contract:
ScripsAmerica, Inc. announced that the Company's acquisition target, Marlex Pharmaceuticals, Inc., has shipped over $1.1 million of product during the initial three months of its multi-year pharmaceutical distribution contract with the US Department of Defense (DOD) and Defense Logistics Agency (DLA).
During the month of January, the company has ramped up its distribution from an average of 700 bottles per month to a minimum of 1,100 bottles per month, representing a 57% increase. This was accomplished because of its manufacturer's ability to produce a larger quantity of the needed pharmaceutical. Given its current production rate, the company is on pace to meet or exceed the $25 million production requirement of its government contract with the DOD.
SCRC Technical Indicators: Closing in the last session at just $0.31 per share, SCRC looks like it could be in for a major breakout very soon and at current levels could prove to be significantly undervalued given its considerable upside potential in the short term.
The 7 Day Average Direction Indicator shows positive directional movement, and the 20 Day Moving Average vs. Price chart shows price has moved above the moving average generating a bullish signal in the short term.
Leading up to the last session, the 8-10 Day Moving Average Hilo Channel showed price action moving above the channel triggering a "buy" action, even as prices pulled back in Friday's session.
The 20 Day Bollinger Bands show narrower bands indicating lessening volatility, and price action in the last session seemed to be moving down towards the lower band, and combined with an RSI or Relative Strength Index less than 70, this could be generating a "BUY" signal as prices look primed to rebound from here.
SCRC is showing the potential for a ferocious start to the New Year!
Strong news and bullish technical's are making SCRC look especially attractive at current levels, so I suggest you begin your research on SCRC immediately and be ready for Monday's trading session as I expect we could see SCRC surge in early morning trading!
Happy Trading!
-James
Disclaimer: (Please Read)
PennyStockProphet.com is engaged in the business of marketing and advertising companies. All content in this communication is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Never invest in any stock featured on the PennyStockProphet.com website or email alerts unless you can afford to lose your entire investment. Many of the stocks featured are highly speculative. PennyStockProphet.com has not received any compensation for this profile coverage of ScripsAmerica Inc. (SCRC). Neither James Connelly nor PennyStockProphet.com employees are registered as investment advisors, financial analysts, brokers, or dealers in any jurisdiction whatsoever. Your use of the PennyStockProphet.com website, email alerts, and all other services means that you agree to hold PennyStockProphet.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation for the purchase or sale of any securities. The information provided is obtained from sources deemed reliable, but PennyStockProphet.com does not guarantee in any way the timeliness, sequence, accuracy, adequacy, or completeness of such information made regarding stocks discussed on PennyStockProphet.com or in email alerts. The owner, publisher, editor and their associates are not responsible for errors and omissions. You understand and agree that at the time of any transaction you make James Connelly, PennyStockProphet.com employees, PennyStockProphet.com affiliates, and friends and family of James Connelly may have a position in such securities. The position may have been acquired prior to the publication of any website information or email alert. You should also be aware that the aforementioned parties do have the right to sell their positions at any time without further notification. Any opinions expressed are subject to change without notice. PennyStockProphet.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or persons affiliated with or associated with such companies; or is available from public sources. Read our full disclaimer at:
18627 Brookhurst St #507 Fountain Valley CA 92708
If you would like to see the promotion performance history for this promoter, you can visit my board and view a more detailed post there.
I use custom software that tracks all major stock promotions and keeps records of their performances. I am NOT affiliated with any stock promoter and I provide this information as a courtesy to supplement your own due diligence.
Visit my IHub board to get alerts on all OTCBB and Pink Sheets stock promotions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
